BioNexus Gene Lab Corp Files 8-K

TL;DR

BioNexus Gene Lab Corp filed an 8-K on 9/18 for an event on 9/14. Check for details.

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on September 18, 2024, reporting an event that occurred on September 14, 2024. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Wyoming and its fiscal year ends on December 31.

Why It Matters

This filing indicates a significant event has occurred for BioNexus Gene Lab Corp, requiring disclosure to the SEC and investors. Investors should review the filing for details on the nature of the event.

Risk Assessment

Risk Level: low — This is a standard regulatory filing with no immediate indication of financial distress or significant operational changes.

Key Numbers

• 001-41750 — SEC File Number (Identifies the company's filing with the SEC)
• 35-2604830 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Registrant
• Wyoming (jurisdiction) — State of incorporation
• September 18, 2024 (date) — Date of report
• September 14, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• bglc_8k.htm (8-K) — 26KB
• bglc_ex991.htm (EX-99.1) — 13KB
• 0001477932-24-005817.txt ( ) — 167KB
• bglc-20240914.xsd (EX-101.SCH) — 6KB
• bglc-20240914_lab.xml (EX-101.LAB) — 15KB
• bglc-20240914_cal.xml (EX-101.CAL) — 1KB
• bglc-20240914_pre.xml (EX-101.PRE) — 9KB
• bglc-20240914_def.xml (EX-101.DEF) — 2KB
• bglc_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On September 14, 2024, BioNexus Gene Lab Corp (the "Company") issued a press release announcing that its wholly owned subsidiary MRNA Scientific Sdn. Bhd. ("MRNA Scientific") has signed a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. ("Vitarray"), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market. Leveraging MRNA Scientific's advanced testing facilities in Kuala Lumpur, the collaboration aims to enhance early disease detection, including for cancer and cardiovascular conditions, while expanding access to molecular diagnostics. Vitarray, authorized by China's Huaxia Jingdu Renhe Medical Laboratory to manage overseas gene detection, will supply samples, and MRNA Scientific will handle testing. The agreement is expected to improve profitability and expanding market reach. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 2

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 99.1 Press Release Dated September 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: September 18, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR